Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company, has announced its participation in two major industry events in September 2024. The company will be part of the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, with an on-demand virtual presentation available from September 9. Additionally, Lisata will present at the 2024 LSX World Congress USA on September 12 at 11:15 a.m. ET in Boston.
Dr. David J. Mazzo, President and CEO of Lisata, will be the presenter at both events. These conferences provide Lisata with opportunities to showcase its innovative therapies for advanced solid tumors and other serious diseases to investors and industry professionals.
Lisata Therapeutics (NASDAQ: LSTA), un'azienda farmaceutica in fase clinica, ha annunciato la sua partecipazione a due importanti eventi del settore a settembre 2024. L'azienda sarà presente alla 26ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright dal 9 all'11 settembre, con una presentazione virtuale on-demand disponibile dal 9 settembre. Inoltre, Lisata presenterà al 2024 LSX World Congress USA il 12 settembre alle 11:15 ET a Boston.
Il Dr. David J. Mazzo, Presidente e CEO di Lisata, sarà il presentatore in entrambi gli eventi. Queste conferenze offrono a Lisata l'opportunità di mostrare le sue terapie innovative per tumori solidi avanzati e altre malattie gravi a investitori e professionisti del settore.
Lisata Therapeutics (NASDAQ: LSTA), una compañía farmacéutica en etapa clínica, ha anunciado su participación en dos importantes eventos de la industria en septiembre de 2024. La empresa formará parte de la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright del 9 al 11 de septiembre, con una presentación virtual a demanda disponible a partir del 9 de septiembre. Además, Lisata presentará en el 2024 Congreso Mundial LSX EE. UU. el 12 de septiembre a las 11:15 a.m. ET en Boston.
El Dr. David J. Mazzo, Presidente y CEO de Lisata, será el presentador en ambos eventos. Estas conferencias brindan a Lisata la oportunidad de mostrar sus terapias innovadoras para tumores sólidos avanzados y otras enfermedades graves a inversores y profesionales del sector.
리사타 테라퓨틱스 (NASDAQ: LSTA), 임상 단계의 제약 회사, 2024년 9월에 있을 두 개의 주요 산업 행사에 참여한다고 발표했습니다. 이 회사는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 9월 9일부터 11일까지 참여하며, 9월 9일부터 주문형 가상 프레젠테이션이 제공됩니다. 또한, 리사타는 9월 12일 오전 11:15 ET에 보스턴에서 열리는 2024 LSX 월드 콩그레스 USA에서 발표할 예정입니다.
리사타의 회장 겸 CEO인 David J. Mazzo 박사가 두 행사에서 발표할 예정입니다. 이러한 회의는 리사타에게 고급 고형 종양 및 기타 심각한 질병을 투자자 및 산업 전문가에게 소개할 기회를 제공합니다.
Lisata Therapeutics (NASDAQ: LSTA), une entreprise pharmaceutique en phase clinique, a annoncé sa participation à deux événements majeurs de l'industrie en septembre 2024. L'entreprise sera présente à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright du 9 au 11 septembre, avec une présentation virtuelle à la demande disponible à partir du 9 septembre. De plus, Lisata présentera au Congrès Mondial LSX 2024 USA le 12 septembre à 11h15 ET à Boston.
Le Dr David J. Mazzo, Président et CEO de Lisata, sera le présentateur lors des deux événements. Ces conférences offrent à Lisata l'occasion de présenter ses thérapies innovantes pour les tumeurs solides avancées et d'autres maladies graves aux investisseurs et aux professionnels de l'industrie.
Lisata Therapeutics (NASDAQ: LSTA), ein in der klinischen Phase befindliches Pharmaunternehmen, hat seine Teilnahme an zwei wichtigen Branchenveranstaltungen im September 2024 angekündigt. Das Unternehmen wird Teil der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September sein, mit einer on-demand virtuellen Präsentation, die ab dem 9. September verfügbar ist. Außerdem wird Lisata am 12. September um 11:15 Uhr ET in Boston auf dem 2024 LSX World Congress USA präsentieren.
Dr. David J. Mazzo, Präsident und CEO von Lisata, wird bei beiden Veranstaltungen präsentieren. Diese Konferenzen bieten Lisata die Möglichkeit, seine innovativen Therapien für fortgeschrittene solide Tumoren und andere schwere Erkrankungen Investoren und Fachleuten der Branche vorzustellen.
- None.
- None.
BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September:
H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024)
Format: Virtual
Presentation: Available on-demand beginning Monday, September 9, 2024
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
For more information on the H.C. Wainwright 26th Annual Global Investment Conference, please visit https://hcwevents.com/annualconference/.
2024 LSX World Congress USA (September 11-12, 2024)
Format: In-person
Location: Hynes Convention Center, Boston, MA
Presentation Date: Thursday, September 12, 2024
Presentation Time: 11:15 a.m. Eastern Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
For more information on the conference and how to register, please visit https://informaconnect.com/lsx-world-congress-usa/.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
FAQ
What events will Lisata Therapeutics (LSTA) participate in during September 2024?
When and where will Lisata Therapeutics (LSTA) present at the 2024 LSX World Congress USA?
Who will be presenting on behalf of Lisata Therapeutics (LSTA) at the September 2024 events?
What type of company is Lisata Therapeutics (LSTA)?
